Cross-Sector entity
Compass Pathways is most often covered alongside FDA, which appears in 4 of these 4 stories. Across a 17-day span, the pace is roughly 1.6 stories per week. Coverage clusters in clinical-trial, which accounts for 2 of those 4, with the remainder spread across 2 other categories.
4 verified stories tracked
Last mentioned: Mar 26, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Compass Pathways is most often covered alongside FDA, which appears in 4 of these 4 stories. Across a 17-day span, the pace is roughly 1.6 stories per week. Coverage clusters in clinical-trial, which accounts for 2 of those 4, with the remainder spread across 2 other categories. The tracked stories average 2.3 original sources each. Compass Pathways appears in 4 tracked Cross-Sector stories published from March 10, 2026 through March 26, 2026.
Computed from the 4 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Compass Pathways. Shared-story counts are live from our verified record — not editorial picks.
King County Resolution
King County Council officially passes the resolution to decriminalize psychedelic mushrooms county-wide.
Anticipated Data Readout
Expected primary endpoint results for the COMP005 Phase 3 trial in TRD.
Fiscal Year End
Closed 2025 with a strategic focus on regulatory filing preparations.
Therapist Training Milestone
Completed training for over 500 facilitators to support Phase 3 delivery protocols.
Phase 3 Expansion
Compass increased the number of active clinical sites for COMP006 to over 50 globally.
WA SB 5263 Passed
Washington Governor signs a bill to create a psilocybin task force and pilot program.
Seattle Decriminalization
Seattle City Council passes a resolution to decriminalize the cultivation and possession of psychedelic plants.
King County has officially passed a resolution to decriminalize the possession and use of psychedelic mushrooms, joining a growing list of Pacific Northwest jurisdictions. This move reflects a significant shift toward viewing psilocybin through a public health lens, potentially paving the way for expanded clinical research and therapeutic access in the region.
Compass Pathways reported its full-year 2025 financial results, highlighting a strategic focus on its pivotal Phase 3 COMP360 program for treatment-resistant depression. With a cash runway extending into late 2026, the company is positioned for a critical year of clinical readouts and regulatory engagement.
Source: finanznachrichten.de · pharmiweb.com
A new comparative study reveals that psychedelic-assisted therapy significantly exceeds the efficacy of standard nicotine patches for long-term smoking cessation. The findings suggest a paradigm shift in treating nicotine addiction, moving from continuous replacement to episodic, transformative intervention.
A landmark study has demonstrated that a single dose of psilocybin, paired with psychological support, significantly outperforms traditional nicotine replacement therapies for long-term smoking cessation. The findings suggest a paradigm shift in treating substance use disorders through psychedelic-assisted therapy.
